BioVersys
Latest round
- Series C
Last raised
- Jan 2023
Total raised
- $33M
Investors
- 7
About BioVersys
BioVersys AG, founded in 2010 by founder and CEO Marc Gitzinger in Basel, Switzerland, focuses on addressing antimicrobial resistance through novel pharmaceutical developments. BioVersys specializes in combating antimicrobial resistance (AMR) through the development of innovative pharmaceutical solutions. Their core offerings include novel antibiotic candidates such as BV100, Alpibectir, BV200, and BV500, each designed to target specific drug-resistant infections. BV100 addresses serious hospital infections caused by Acinetobacter baumannii, while Alpibectir focuses on multidrug-resistant tuberculosis (MDR-TB) and TB meningitis. These products possess unique modes of action, aiming to overcome existing antibiotics' limitations and restore treatment efficacy.The revenue model of BioVersys is built around partnerships with healthcare institutions and pharmaceutical companies, leveraging collaborative agreements to facilitate the development and commercialization of their products. This includes direct B2B transactions where hospitals and healthcare providers purchase their antibiotic innovations to enhance treatment options for resistant infections. Additionally, BioVersys engages in strategic collaborations that may involve milestone payments or royalties based on the commercial success of their drug candidates. Specific pricing structures for their products are established during negotiations with healthcare partners, reflecting the critical nature of these therapeutics in addressing serious infectious diseases.to conduct a Phase 2b trial of BV100 via ADVANCE-ID, expand treatment arms, enroll CRAB patients, and generate pivotal data for Phase 3 regulatory submissions.
Who invested in BioVersys
7 investors across 4 rounds
See all investors in BioVersys
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BioVersys
Who invested in BioVersys?
BioVersys has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BioVersys raised?
BioVersys has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did BioVersys last raise money?
BioVersys's most recent round on record is a Series C, in Jan 2023.
What does BioVersys do?
BioVersys AG, founded in 2010 by founder and CEO Marc Gitzinger in Basel, Switzerland, focuses on addressing antimicrobial resistance through novel pharmaceutical developments.
Where is BioVersys headquartered?
BioVersys is headquartered in Basel, Switzerland.
Which VCs invest in companies like BioVersys?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at BioVersys's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like BioVersys? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.